Dual-Chamber Drug Delivery Devices in 2026: Formulation Challenges, Leading Suppliers and Pharma Opportunities

Why Dual-Chamber Devices Matter for Injectable Medicines Three Important Industry Signals NEMLUVIO: An Approved Example of Dual-Chamber Technology How Dual-Chamber Drug Delivery Systems Work Leading Suppliers and Manufacturing Partners to Evaluate Where Are the Commercial Opportunities? What Manufacturers Must Evaluate Before Selecting a Device What Should Companies Track in 2026–2027? How Towards Healthcare Supports Dual-Chamber Device Business Development

Why Dual-Chamber Devices Matter for Injectable Medicines

Some injectable medicines lose stability when the active ingredient remains mixed with its diluent during storage. Others require a freeze-dried formulation to be reconstituted immediately before administration.

Dual-chamber drug delivery systems address this challenge by keeping two components separated inside a single device until preparation is required. Depending on the design, the system can combine a lyophilized drug with a liquid diluent or deliver two compatible formulations sequentially.

These systems can reduce preparation steps and support more convenient administration. However, each device must be compatible with the drug formulation, dose, storage conditions and intended route of administration.

Download Sample: https://www.towardshealthcare.com/download-sample/6867

Three Important Industry Signals

Industry indicator	Reported figure or example	Why it matters
Dual-chamber prefilled syringes	38.1% of global segment revenue in 2025	Identifies the leading product format in the Grand View Research analysis
Global dual-chamber drug delivery systems	$573.4 million estimated revenue in 2025	Provides a baseline for assessing supplier and development opportunities
NEMLUVIO dual-chamber pen	30 mg lyophilized nemolizumab-ilto plus water for injection	Demonstrates commercial use of a dual-chamber pen for a biologic medicine

Grand View Research estimates the segment could reach $1.03 billion by 2033, with a projected CAGR of 7.7% from 2026 to 2033. These are third-party estimates, not audited industry totals. <Cite refs={["turn151792search0","turn151792search1"]}/>

NEMLUVIO: An Approved Example of Dual-Chamber Technology

NEMLUVIO, developed by Galderma, received US FDA approval on August 12, 2024, for adults with prurigo nodularis. The product uses a single-dose, prefilled dual-chamber pen containing lyophilized nemolizumab-ilto in one chamber and water for injection in the other. The medicine must be reconstituted before administration. <Cite refs={["turn151792search3","turn151792search1"]}/>

This example illustrates how the delivery device forms part of the overall drug product rather than functioning as a generic container alone.

For pharmaceutical developers, the commercial implications include:

Selecting a device that accommodates the formulation's stability requirements.
Ensuring the mixing process is reliable and repeatable.
Testing dose delivery, container closure integrity and material compatibility.
Designing instructions that patients and healthcare professionals can follow correctly.
Coordinating drug development, device development, manufacturing and regulatory submissions.

NEMLUVIO is one example, not proof that all biologics require a dual-chamber device. The formulation and intended use determine whether this design is appropriate.

How Dual-Chamber Drug Delivery Systems Work

A typical dual-chamber syringe or cartridge uses two compartments separated by a stopper. A bypass or transfer mechanism allows the components to mix when the device is activated.

The process generally involves three stages:

Separate storage: The drug and diluent remain isolated during storage.
Reconstitution or transfer: The device mechanism allows the components to mix, or supports sequential delivery where the design permits.
Administration: The prepared dose is delivered using the intended injection system.

SCHOTT Pharma offers dual-chamber syringes and cartridges designed for applications such as lyophilized drug reconstitution. Its cartridge platform can also support sequential injection of two drug solutions where the specific system is designed for that purpose. <Cite refs={["turn481963search0","turn481963search2"]}/>

Leading Suppliers and Manufacturing Partners to Evaluate

The supply chain includes primary-container manufacturers, delivery-device developers and contract manufacturers with suitable filling capabilities.

Company	Relevant capability	Potential role in a dual-chamber project
SCHOTT Pharma	Dual-chamber syringes and glass cartridges	Primary containers for drug storage, reconstitution and administration
Vetter	Aseptic syringe filling, including dual-chamber systems	Fill-finish manufacturing partner for suitable drug products
Gerresheimer	Pharmaceutical glass cartridges and drug delivery components	Container and packaging solutions; project-specific dual-chamber capability must be confirmed
Phillips Medisize	Drug delivery device development and manufacturing	Potential device-development or manufacturing partner, subject to format and project requirements

Sources: SCHOTT Pharma product information, Vetter's sterile syringe filling capabilities, Gerresheimer's cartridge portfolio and the ONdrugDelivery 2025 review of dual-chamber drug delivery systems. <Cite refs={["turn481963search0","turn481963search2","turn481963search1","turn481963search13","turn151792search35"]}/>

These companies should not be treated as interchangeable suppliers. A primary-container manufacturer may not provide a complete pen or autoinjector, while a fill-finish CDMO may not own the device design. Buyers need to verify the exact format, manufacturing site, scale, regulatory support and integration capabilities for each project.

Where Are the Commercial Opportunities?

1. Biologics and Lyophilized Medicines

Some sensitive injectable formulations need separate storage of the active ingredient and diluent. Dual-chamber systems can be considered when conventional vials or separate preparation steps do not meet the product's stability, usability or administration requirements.

Opportunity: Identify drug developers with lyophilized injectable products and evaluate whether a dual-chamber syringe, cartridge or pen could meet their needs.

2. Device Engineering and Design

A dual-chamber system must do more than store two components. The mixing mechanism, stopper movement, injection force, delivered dose and container integrity all require careful design and testing.

Opportunity: Device developers can differentiate through dependable mixing, dose accuracy, intuitive operation, robust container closure and compatibility with existing injection platforms.

3. Fill-Finish and Contract Manufacturing

Dual-chamber formats can require specialized filling, assembly, inspection and process validation. Not every standard syringe line can handle every dual-chamber configuration.

Vetter states that its sterile syringe filling capabilities include single- and dual-chamber systems, with specific formats and configurations depending on the facility and project. <Cite refs={["turn481963search1"]}/>

Opportunity: CDMOs can identify drug developers approaching clinical or commercial manufacturing milestones and assess whether their existing lines can support the required format.

4. Licensing and Pharmaceutical Partnerships

A pharmaceutical company may need a container supplier, a device-development partner, a fill-finish provider or an integrated solution. These needs can emerge at different stages of drug development.

Opportunity: Map the product pipeline, identify the drug owner, assess the formulation and administration requirements, and connect the company with qualified suppliers.

What Manufacturers Must Evaluate Before Selecting a Device

Evaluation area	Questions to investigate
Formulation compatibility	Does the drug remain stable in contact with the selected materials and diluent after mixing?
Container integrity	Can the system maintain the required barrier and closure performance throughout shelf life?
Mixing performance	Does the design achieve consistent reconstitution without unacceptable residual volume or incomplete mixing?
Dose delivery	Can the device deliver the intended dose consistently and reliably?
Usability	Can the intended user prepare and administer the medicine correctly?
Manufacturing readiness	Are filling, assembly, inspection and sterilization processes suitable for the chosen design?
Regulatory pathway	What drug-device combination requirements and evidence apply in each target jurisdiction?

The selection process should involve formulation scientists, device engineers, quality teams, regulatory specialists and manufacturing partners from the early development stages.

What Should Companies Track in 2026–2027?

For pharmaceutical and medical device businesses, a useful intelligence program should monitor:

New injectable products using dual-chamber syringes, cartridges and pens.
Drug candidates that use lyophilized formulations or require reconstitution.
Patents covering chamber design, transfer mechanisms and device operation.
Supplier capabilities in glass containers, polymer components and delivery systems.
CDMO investments in specialized filling and assembly lines.
Licensing agreements and partnerships between drug developers and device manufacturers.
Regulatory approvals, product launches and changes in administration format.

Patent ownership, platform compatibility and supplier availability should be verified at the individual product level. A company having a general prefilled-syringe portfolio does not automatically mean it offers a compatible dual-chamber system.

How Towards Healthcare Supports Dual-Chamber Device Business Development

Towards Healthcare Research & Consulting helps pharmaceutical and medical device teams turn product and supplier intelligence into actionable commercial plans.

Complete Master Datasets: Map pharmaceutical developers, injectable products, delivery formats and supplier capabilities.
Competitive Quadrants: Compare device manufacturers and relevant platform capabilities.
Customized Dashboards: Track product launches, development milestones, partnerships and competitive activity.
Buyer Identification: Identify potential pharma customers, licensing partners and CDMO opportunities.
GTM Strategy: Prioritize target accounts, evaluate regional opportunities and plan partner outreach.

Which pharmaceutical companies need a dual-chamber delivery partner? Identify high-potential buyers, compare competing platforms and uncover licensing and manufacturing opportunities with Towards Healthcare.

Contact [email protected] for customized device intelligence and buyer identification.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram

About the Author

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.